{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers type I interferon signaling.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        },
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Results derived from specific models requiring careful translation to broad clinical settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination broadens tumor antigen display.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Effects are based on preclinical metrics and may vary across distinct tumor types."
    },
    {
      "claim_id": "C03",
      "claim": "Prior mRNA vaccination is associated with improved survival in patients receiving ICI.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Retrospective observational design and varied vaccination timing limit definitive causal interpretation."
    },
    {
      "claim_id": "C04",
      "claim": "Combination therapy increases immune infiltration into tumors.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |",
          "line_ref": "L33"
        },
        {
          "quote": "5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Increased infiltration measured in mouse models may not uniformly guarantee clinical response in all human tumors."
    }
  ]
}